Home › Therapeutic areas › Other blood and body fluid agents
Japan market screening · Therapeutic class
その他の血液・体液用薬 · Japan Standard Commodity Classification
28 molecules in this class are marketed in Japan across 205 products. 20 of those products are not shipping normally today — 9.8% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.
Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.
| Molecule | Products | Companies | Constrained | Supply mix |
|---|---|---|---|---|
| Clopidogrel Sulfateクロピドグレル硫酸塩 | 39 | 18 | 1 | |
| Cilostazolシロスタゾール | 34 | 11 | 7 | |
| Sarpogrelate Hydrochlorideサルポグレラート塩酸塩 | 24 | 12 | 4 | |
| Ethyl Icosapentateイコサペント酸エチル | 22 | 8 | — | |
| Prasugrel Hydrochlorideプラスグレル塩酸塩 | 15 | 4 | 1 | |
| Beraprost Sodiumベラプロストナトリウム | 13 | 8 | 2 | |
| Aspirinアスピリン | 11 | 10 | 1 | |
| Limaprost Alfadexリマプロスト アルファデクス | 6 | 4 | 1 | |
| Filgrastim (Genetical Recombination)フィルグラスチム（遺伝子組換え） | 5 | 1 | — | |
| Ticlopidine Hydrochlorideチクロピジン塩酸塩 | 5 | 4 | 1 | |
| Clopidogrel Sulfate / Aspirinクロピドグレル硫酸塩・アスピリン | 4 | 4 | — | |
| Filgrastim (Genetical Recombination) [Filgrastim Biosimilar 1]フィルグラスチム（遺伝子組換え）［フィルグラスチム後続１］ | 3 | 1 | — | |
| Filgrastim (Genetical Recombination) [Filgrastim Biosimilar 2]フィルグラスチム（遺伝子組換え）［フィルグラスチム後続２］ | 3 | 1 | — | |
| Lenograstim (Genetical Recombination)レノグラスチム（遺伝子組換え） | 3 | 1 | — | |
| Luspatercept (Genetical Recombination)ルスパテルセプト（遺伝子組換え） | 2 | 1 | — | |
| Pegfilgrastim (Genetical Recombination)ペグフィルグラスチム（遺伝子組換え） | 2 | 1 | — | |
| Pegfilgrastim (Genetical Recombination) [Pegfilgrastim Biosimilar 1]ペグフィルグラスチム（遺伝子組換え）［ペグフィルグラスチム後続１］ | 2 | 2 | 2 | |
| Ticagrelorチカグレロル | 2 | 1 | — | |
| Andexanet Alfa (Genetical Recombination)アンデキサネット アルファ（遺伝子組換え） | 1 | 1 | — | |
| Apadamtase Alfa (Genetical Recombination) / Cinaxadamtase Alfa (Genetical Recombination)アパダムターゼ アルファ（遺伝子組換え）・シナキサダムターゼ アルファ（遺伝子組換え） | 1 | 1 | — | |
| Aspirin / Lansoprazoleアスピリン・ランソプラゾール | 1 | 1 | — | |
| Aspirin / Vonoprazan Fumarateアスピリン・ボノプラザンフマル酸塩 | 1 | 1 | — | |
| Avatrombopag Maleateアバトロンボパグマレイン酸塩 | 1 | 1 | — | |
| Caplacizumab (Genetical Recombination)カプラシズマブ（遺伝子組換え） | 1 | 1 | — | |
| Idarucizumab (Genetical Recombination)イダルシズマブ（遺伝子組換え） | 1 | 1 | — | |
| Lusutrombopagルストロンボパグ | 1 | 1 | — | |
| Plerixaforプレリキサホル | 1 | 1 | — | |
| Trometamolトロメタモール | 1 | 1 | — |
Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.
Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.
Send an enquiryOur Database Division replies in English within three business days (Japan time).